Bacterial Vaginosis – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Bacterial
Vaginosis – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Bacterial Vaginosis – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for
Bacterial Vaginosis (Infectious Disease), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Bacterial Vaginosis (Infectious Disease)
pipeline guide also reviews of key players involved in therapeutic
development for Bacterial Vaginosis and features dormant and
discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase II, Phase I and Preclinical stages are 1, 6,
1 and 3 respectively. Similarly, the Universities portfolio in Discovery
stages comprises 1 molecule, respectively.

Bacterial Vaginosis (Infectious Disease) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Bacterial Vaginosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Bacterial
  Vaginosis (Infectious Disease) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Bacterial
  Vaginosis (Infectious Disease) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Bacterial Vaginosis (Infectious Disease)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Bacterial Vaginosis (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Bacterial Vaginosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Bacterial Vaginosis (Infectious Disease) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Featured News & Press Releases

• Sep 21, 2018: New Data on Patient Acceptability and Genitourinary
  Effects of Evofem Biosciences’ Amphora and its Role as a Multipurpose
  Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American
  Society For Reproductive Medicine Annual Congress
• Jul 09, 2018: VivaGel BV NDA advances to next stage of FDA review
• Apr 30, 2018: Starpharma completes US New Drug Application for VivaGel
  BV
• Jan 18, 2018: Melinta Therapeutics Announces Initiation of Program for
  Radezolid in Patients with Bacterial Vaginosis
• Jan 17, 2018: Osel’s LACTIN-V Enters Clinical Study to Improve the
  Success Rate of IVF in Women With Imbalanced Vaginal Microbiomes
• Nov 21, 2017: Starpharma: NDA submission for VivaGel BV in the US
• Oct 25, 2017: VivaGel BV granted marketing approval in Australia
• Aug 07, 2017: Successful VivaGel Phase 3 results and NDA planned for
  rBV
• Jul 27, 2017: Evofem Biosciences Announces First Patient Enrolled in a
  Phase 3 Clinical Trial of AMPHORA for Prevention of Pregnancy
• Jul 04, 2017: VivaGel BV phase 3 results timing and commercialisation
• Jun 29, 2017: AMPHORA (L-lactic Acid, citric acid, and potassium
  bitartrate) Receives “Qualified Infectious Disease Product” (QIDP)
  Designation from the FDA
• Mar 30, 2017: VivaGel BV phase 3 trials for prevention of BV completed
• Jan 12, 2017: VivaGel BV granted QIDP and Fast Track designation by US
  FDA
• Oct 13, 2016: Enrolment complete for Phase 3 VivaGel BV-R program
• Aug 17, 2016: Evofem Announces First Patient Enrolled in a Clinical
  Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH

Companies Mentioned

• Dare Bioscience Inc.
• Evofem Biosciences Inc.
• Melinta Therapeutics Inc.
• Osel Inc.
• Pharmiva AB
• Starpharma Holdings Ltd.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7gi859

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs